Business Description
ATAI Life Sciences NV
ISIN : NL0015000DX5
Compare
Compare
Traded in other countries / regions
ATAI.USA9VC.GermanyATAI.Mexico IPO Date
2021-11-17Description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5.11 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | -0.72 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 0.05 | |||||
Beneish M-Score | 2.03 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 27.6 | |||||
3-Year EPS without NRI Growth Rate | 14.9 | |||||
3-Year FCF Growth Rate | -57.7 | |||||
3-Year Book Growth Rate | 34.7 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 40.47 | |||||
9-Day RSI | 37.89 | |||||
14-Day RSI | 36.64 | |||||
6-1 Month Momentum % | 4.33 | |||||
12-1 Month Momentum % | -0.69 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.83 | |||||
Quick Ratio | 7.83 | |||||
Cash Ratio | 7.08 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3 | |||||
Shareholder Yield % | -2.84 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -41044.04 | |||||
Net Margin % | -12203.25 | |||||
FCF Margin % | -30693.8 | |||||
ROE % | -14.31 | |||||
ROA % | -12.03 | |||||
ROIC % | -152.06 | |||||
ROC (Joel Greenblatt) % | -1264.56 | |||||
ROCE % | -11.08 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1350 | |||||
PB Ratio | 1.01 | |||||
Price-to-Tangible-Book | 1 | |||||
EV-to-EBIT | -4.83 | |||||
EV-to-Forward-EBIT | -0.86 | |||||
EV-to-EBITDA | -4.89 | |||||
EV-to-Forward-EBITDA | -1.3 | |||||
EV-to-Revenue | 507.43 | |||||
EV-to-Forward-Revenue | 187.41 | |||||
EV-to-FCF | -1.64 | |||||
Price-to-Net-Current-Asset-Value | 3.14 | |||||
Price-to-Net-Cash | 3.72 | |||||
Earnings Yield (Greenblatt) % | -20.7 | |||||
FCF Yield % | -37.93 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ATAI Life Sciences NV Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.258 | ||
EPS (TTM) (€) | -0.217 | ||
Beta | 0 | ||
Volatility % | 70.97 | ||
14-Day RSI | 36.64 | ||
14-Day ATR (€) | 0.048461 | ||
20-Day SMA (€) | 1.2753 | ||
12-1 Month Momentum % | -0.69 | ||
52-Week Range (€) | 0.965 - 2.47 | ||
Shares Outstanding (Mil) | 167.41 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
ATAI Life Sciences NV Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
ATAI Life Sciences NV Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
ATAI Life Sciences NV Frequently Asked Questions
What is ATAI Life Sciences NV(XTER:9VC)'s stock price today?
The current price of XTER:9VC is €1.23. The 52 week high of XTER:9VC is €2.47 and 52 week low is €0.97.
When is next earnings date of ATAI Life Sciences NV(XTER:9VC)?
The next earnings date of ATAI Life Sciences NV(XTER:9VC) is 2024-08-09 Est..
Does ATAI Life Sciences NV(XTER:9VC) pay dividends? If so, how much?
ATAI Life Sciences NV(XTER:9VC) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |